 |
|
|
|
|
|
 |
Top 50 Pharma |
|
|
| Title |
 |
Publication Date |
 |
Price |
|
|
|
|
Merck & Co., Inc. - SWOT Analysis
SWOT Analysis
|
May 2008 |
£63 |
Amgen Inc. - SWOT Analysis
SWOT Analysis
|
April 2008 |
£63 |
Biogen Idec, Inc.
SWOT Analysis
|
April 2008 |
£63 |
Pfizer Inc
SWOT Analysis
|
April 2008 |
£63 |
Shire plc - SWOT Analysis
SWOT Analysis
|
April 2008 |
£63 |
Alcon
Pipeline,Products,Performance,Potential
|
March 2008 |
£595 |
Abbott Laboratories
Pipeline,Products,Performance,Potential
|
March 2008 |
£595 |
Shionogi:
Pipeline • Products • Performance • Potential
|
March 2008 |
£595 |
Ono: Pipeline • Products • Performance • Potential
|
February 2008 |
£595 |
Astellas Pharma
Performance, Products, Pipeline and Potential
|
February 2008 |
£595 |
Bristol-Myers Squibb
Pipeline, Products, Performance, Potential
|
February 2008 |
£595 |
Allergan: Pipeline , Products , Performance , Potential
|
February 2008 |
£595 |
Novartis
Pipeline Products Performance Potential
|
February 2008 |
£595 |
Johnson & Johnson Medical Device Company Intelligence Report
|
December 2007 |
£695 |
Boehringer Ingelheim Gmbh
Pharmavitae Profile
|
December 2007 |
£2995 |
Solvay S.A.
Pharmavitae Profile
|
December 2007 |
£2995 |
Astrazeneca Plc (Incl. Medimmune Inc.)
Pharmavitae Profile
|
December 2007 |
£2995 |
Biogen Idec Inc.
Pharmavitae Profile
|
December 2007 |
£2995 |
Abbott Laboratories
Pharmavitae Profile
|
December 2007 |
£2995 |
Amgen Inc.
Pharmavitae Profile
|
December 2007 |
£2995 |
Astellas Pharma Inc.
Pharmavitae Profile
|
December 2007 |
£2995 |
Eisai Co., Ltd
Pharmavitae Profile
|
December 2007 |
£2995 |
Bristol-Myers Squibb Co.
Pharmavitae Profile
|
December 2007 |
£2995 |
Johnson & Johnson
|
December 2007 |
£2995 |
Shionogi & Co., Ltd
Pharmavitae Profile
|
December 2007 |
£2995 |
Merck & Co., Inc.
Pharmavitae Profile
|
December 2007 |
£2995 |
Pfizer Inc.
Pharmavitae Profile
|
December 2007 |
£2995 |
Shire Plc
Pharmavitae Profile
|
December 2007 |
£2995 |
Takeda Pharmaceutical Co., Ltd
Pharmavitae Profile
|
December 2007 |
£2995 |
Forest Laboratories Inc.
Pharmavitae Profile
|
December 2007 |
£2995 |
Eli Lilly & Co.
Pharmavitae Profile
|
December 2007 |
£2995 |
Gilead Sciences Inc.
Pharmavitae Profile
|
December 2007 |
£2995 |
H. Lundbeck A/S
Pharmavitae Profile
|
December 2007 |
£2995 |
Sanofi-Aventis
Pharmavitae Profile
|
December 2007 |
£2995 |
Wyeth
Pharmavitae Profile
|
December 2007 |
£2995 |
AstraZeneca: Pipeline, Products, Performance, Potential
|
November 2007 |
£595 |
Roche: Pipeline, Products, Performance, Potential
|
November 2007 |
£595 |
Astellas Pharma: Pipeline, Products, Performance, Potential
|
November 2007 |
£595 |
Ono: Pipeline, Products, Performance, Potential
|
November 2007 |
£595 |
Takeda: Pipeline, Products, Performance, Potential
|
November 2007 |
£595 |
Biosimilars Benchmarking the key players
PharmaVitae Profile
|
November 2007 |
£2995 |
Stakeholder Opinions Gynecological Cancers
Niche opportunities in advanced disease
|
November 2007 |
£2995 |
Novo Nordisk IMS Company Profile
|
November 2007 |
£510 |
Merck & Co IMS Company Profile
|
November 2007 |
£510 |
Pfizer IMS Company Profile
|
November 2007 |
£510 |
Forest IMS Company Profile
|
November 2007 |
£510 |
Wyeth IMS Company Profile
|
November 2007 |
£510 |
Eisai Prospects to 2110
Pipeline Products Performance Potential
|
October 2007 |
£595 |
Merck & Co Pharmaceutical Company Intelligence Report
Pipeline Products Performance Potential
|
October 2007 |
£595 |
Mitsubishi Pharma:
Pipeline, Products, Performance, Potential
|
October 2007 |
£595 |
Genentech: PharmaVitae Profile
Pharmavitae Profile
|
October 2007 |
£2995 |
Stakeholder Opinions Melanoma
Lucrative commercial opportunities persist
|
October 2007 |
£2995 |
Eisai Co., Ltd. - SWOT Analysis
|
October 2007 |
£63 |
AstraZeneca PLC - SWOT Analysis
|
October 2007 |
£63 |
Sanofi-aventis
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
Eli Lilly
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
Pfizer Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
Roche: Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
Solvay Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
Merck KGaA
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
Watson
Pharmavitae Generics Profile
|
September 2007 |
£2000 |
Novo Nordisk A/S - SWOT Analysis
|
September 2007 |
£125 |
Novartis AG - SWOT Analysis
|
September 2007 |
£125 |
Shionogi & Co., Ltd. - SWOT Analysis
|
September 2007 |
£125 |
Sanofi-Aventis - SWOT Analysis
|
September 2007 |
£125 |
Biogen Idec: Deal Making Profile
|
September 2007 |
£245 |
Genentech: Deal Making Profile
|
September 2007 |
£245 |
Bayer: Deal Making Profile
|
September 2007 |
£245 |
Eli Lilly: Deal Making Profile
|
September 2007 |
£245 |
Eisai: Deal Making Profile
|
September 2007 |
£245 |
Boehringer Ingelheim: Deal Making Profile
|
September 2007 |
£245 |
Astellas Pharma: Deal Making Profile
|
September 2007 |
£245 |
Alcon Labs: Deal Making Profile
|
September 2007 |
£245 |
Abbott Laboratories: Deal Making Profile
|
September 2007 |
£245 |
Allergan: Deal Making Profile
|
September 2007 |
£245 |
Genzyme: Deal Making Profile
|
September 2007 |
£245 |
Baxter: Deal Making Profile
|
September 2007 |
£245 |
AstraZeneca: Deal Making Profile
|
September 2007 |
£245 |
Bayer Schering: Deal Making Profile
|
September 2007 |
£245 |
Mitsubishi Pharma: Deal Making Profile
|
September 2007 |
£245 |
Solvay: Deal Making Profile
|
September 2007 |
£245 |
Shire: Deal Making Profile
|
September 2007 |
£245 |
Schering Plough: Deal Making Profile
|
September 2007 |
£245 |
Takeda: Deal Making Profile
|
September 2007 |
£245 |
Teva: Deal Making Profile
|
September 2007 |
£245 |
Wyeth: Deal Making Profile
|
September 2007 |
£245 |
Watson: Deal Making Profile
|
September 2007 |
£245 |
UCB: Deal Making Profile
|
September 2007 |
£245 |
Sanofi-Aventis: Deal Making Profile
|
September 2007 |
£245 |
Roche: Deal Making Profile
|
September 2007 |
£245 |
Lundbeck: Deal Making Profile
|
September 2007 |
£245 |
King Pharma: Deal Making Profile
|
September 2007 |
£245 |
Johnson & Johnson: Deal Making Profile
|
September 2007 |
£245 |
Merck & Co: Deal Making Profile
|
September 2007 |
£245 |
Novartis: Deal Making Profile
|
September 2007 |
£245 |
Pfizer: Deal Making Profile
|
September 2007 |
£245 |
Otsuka: Deal Making Profile
|
September 2007 |
£245 |
Novo Nordisk: Deal Making Profile
|
September 2007 |
£245 |
Gilead Sciences: Deal Making Profile
|
September 2007 |
£245 |
Amgen: Deal Making Profile
|
September 2007 |
£245 |
Otsuka
Prospects to 2010
|
August 2007 |
£595 |
Boehringer Ingelheim
Prospects to 2010
|
August 2007 |
£595 |
Wyeth Prospects to 2010
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
Daiichi Sankyo
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
AstraZeneca
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
Lundbeck Pharmaceutical Company Intelligence Report
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
Bayer
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
Shionogi
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
Teva Pharmaceutical Industries - SWOT Analysis
|
July 2007 |
£63 |
Johnson & Johnson Prospects to 2010
|
June 2007 |
£595 |
Astellas Pharma - SWOT Analysis
|
May 2007 |
£63 |
Tanabe Seiyaku Co., Ltd. - SWOT Analysis
|
May 2007 |
£63 |
Novo Nordisk Pharmaceutical Company Intelligence Report
Prospects to 2010
|
May 2007 |
£595 |
Amgen
Prospects to 2010
|
May 2007 |
£595 |
Daiichi Sankyo, Ltd. - SWOT Analysis
|
May 2007 |
£63 |
King Pharmaceuticals, Inc - SWOT Analysis
|
May 2007 |
£63 |
Genzyme Corporation - SWOT Analysis
|
May 2007 |
£63 |
Allergan, Inc. - SWOT Analysis
|
May 2007 |
£63 |
Roche IMS Company Profile
|
May 2007 |
£510 |
Bayer Company Profile
|
May 2007 |
£510 |
Allergan IMS Company Profile
|
May 2007 |
£510 |
Baxter IMS Company Profile
|
May 2007 |
£510 |
Takeda IMS Company Profile
|
May 2007 |
£510 |
Sanofi-Aventis IMS Company Profile
|
May 2007 |
£510 |
Biogen Idec IMS Company Profile
|
May 2007 |
£510 |
Boehringer Ingelheim IMS Company Profile
|
May 2007 |
£510 |
Biogen Idec: PharmaVitae Profile
PharmaVitae Profile
|
March 2007 |
£2995 |
Johnson & Johnson IMS Company Profile
|
February 2007 |
£510 |
Genentech IMS Company Profile
|
February 2007 |
£510 |
Amgen IMS Company Profile
|
February 2007 |
£510 |
Daiichi Sankyo IMS Company Profile
|
February 2007 |
£510 |
Daiichi Sankyo: PharmaVitae Profile
PharmaVitae Profile
|
January 2007 |
£3000 |
Wyeth: PharmaVitae Profile
PharmaVitae Profile
|
January 2007 |
£3000 |
Novartis
PharmaVitae Profile
|
January 2007 |
£2995 |
UCB IMS Company Profile
|
January 2007 |
£510 |
Allergan: PharmaVitae Profile
PharmaVitae Profile
|
December 2006 |
£3000 |
Shionogi: PharmaVitae Profile
PharmaVitae Profile
|
December 2006 |
£3000 |
Bayer Schering Pharma: PharmaVitae Profile
PharmaVitae Profile
|
December 2006 |
£3000 |
Bristol-Myers Squibb IMS Company Profile
|
December 2006 |
£510 |
Abbott IMS Company Profile
|
December 2006 |
£510 |
Novartis IMS Company Profile
|
December 2006 |
£510 |
GlaxoSmithKline IMS Company Profile
|
December 2006 |
£510 |
Astellas IMS Company Profile
|
December 2006 |
£510 |
AstraZeneca IMS Company Profile
|
December 2006 |
£510 |
Watson IMS Company Profile
|
December 2006 |
£510 |
Lilly IMS Company Profile
|
December 2006 |
£510 |
Eisai IMS Company Profile
|
December 2006 |
£510 |
Serono IMS Company Profile
|
December 2006 |
£510 |
Schering AG
Prospects to 2010
|
November 2006 |
£895 |
Lundbeck: PharmaVitae Profile
|
November 2006 |
£3000 |
Genzyme
PharmaVitae Profile
|
November 2006 |
£3000 |
Eisai: PharmaVitae Profile
|
November 2006 |
£3000 |
Eisai
PharmaVitae Profile
|
November 2006 |
£3000 |
Serono Prospects to 2010
Prospects to 2010
|
November 2006 |
£795 |
Merck & Co: PharmaVitae Profile
|
November 2006 |
£3000 |
Merck & Co
PharmaVitae Profile
|
November 2006 |
£3000 |
Boehringer Ingelheim: PharmaVitae Profile
PharmaVitae Profile
|
October 2006 |
£3000 |
Shire: PharmaVitae Profile
PharmaVitae Profile
|
October 2006 |
£3000 |
AstraZeneca: PharmaVitae Profile
PharmaVitae Profile
|
October 2006 |
£3000 |
Novo Nordisk: PharmaVitae Profile
PharmaVitae Profile
|
October 2006 |
£3000 |
King Pharmaceuticals IMS Company Profile
|
October 2006 |
£510 |
Serono: PharmaVitae Profile
PharmaVitae Profile
|
October 2006 |
£3000 |
Takeda: PharmaVitae Profile
PharmaVitae Profile
|
October 2006 |
£3000 |
Bayer IMS Company Profile
|
October 2006 |
£510 |
Sanofi-Aventis: PharmaVitae Profile
PharmaVitae Profile
|
September 2006 |
£3000 |
Schering-Plough: PharmaVitae Profile
PharmaVitae Profile
|
September 2006 |
£3000 |
Actavis
IMS Company Profile
|
September 2006 |
£510 |
Dainippon Sumitomo Pharma Co Ltd Deals Briefing
Partneringdesk
|
June 2006 |
£215 |
OTC Healthcare Company Profile - Novartis AG
|
May 2006 |
£195 |
GlaxoSmithKline
|
April 2006 |
£200 |
Novo Nordisk
|
April 2006 |
£200 |
Eli Lilly and Company
|
April 2006 |
£200 |
GlaxoSmithKline
|
April 2006 |
£200 |
Abbott
|
April 2006 |
£200 |
Spotlight Report Series: Deal Making Spotlight on GlaxoSmithKline
|
April 2006 |
£350 |
Spotlight Report Series: Deal Making Spotlight on Pfizer
|
April 2006 |
£350 |
Spotlight Report Series: Deal Making Spotlight on Johnson & Johnson
|
April 2006 |
£350 |
Spotlight Report Series: Deal Making Spotlight on Novartis
|
April 2006 |
£350 |
Spotlight Report Series: Deal Making Spotlight on Sanofi-Aventis
|
April 2006 |
£350 |
Pipeline Insight: Antihypertensives
Weak pipeline leaves innovation to Novartis
|
March 2006 |
£6495 |
Johnson & Johnson Inc
|
February 2006 |
£195 |
Baxter International Medical Device Company Intelligence Report
|
October 2005 |
£295 |
Pfizer Global and US Analysis
PharmaVitae 2005
|
October 2005 |
£3295 |
Bristol-Myers Squibb Co
OTC Healthcare Company Profile
|
September 2005 |
£195 |
GlaxoSmithKline
OTC Healthcare Company Profile
|
August 2005 |
£195 |
Amgen: Profile, Patents and Pipeline
Profile, Patents and Pipeline
|
August 2005 |
£250 |
PharmaVitae 2005: Johnson & Johnson Global Analysis
|
July 2005 |
£2000 |
PharmaVitae 2005: Johnson & Johnson Global & US Analysis
|
July 2005 |
£3000 |
Wyeth Deals
Partneringdesk briefing
|
July 2005 |
£215 |
AstraZeneca Deals
Partneringdesk briefing
|
July 2005 |
£215 |
GlaxoSmithKline Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Eli Lilly and Company Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Novartis AG Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Pfizer Inc Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Schering-Plough Corporation Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Merck & Co Inc Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Bristol-Myers Squibb Company Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Amgen Inc Deals
Partneringdesk briefing
|
July 2005 |
£215 |
H Lundbeck Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Bayer AG Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Johnson & Johnson Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Serono SA Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Abbott Laboratories Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Shire Pharmaceuticals Group PLC Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Roche Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Solvay SA Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Daiichi Pharmaceutical Co Ltd Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Boehringer Ingelheim GmbH Deals
Partneringdesk briefing
|
July 2005 |
£215 |
OTC Healthcare Company Profile - Schering Plough Corp
|
July 2005 |
£195 |
OTC Healthcare Company Profile - Wyeth
|
July 2005 |
£195 |
OTC Healthcare Company Profile - Pfizer Inc
|
July 2005 |
£195 |
OTC Healthcare Company Profile - Bayer AG
|
July 2005 |
£195 |
Bayer AG
|
July 2005 |
£195 |
Eisai Co Ltd Deals
Partneringdesk briefing
|
July 2005 |
£215 |
Boehringer Sohn, CH
OTC Healthcare Company Profile
|
July 2005 |
£195 |
Respiratory Handbook 2005-15
Novartis Moving Into the Major League
|
June 2005 |
£2000 |
PharmaVitae 2005: Roche Global Analysis
|
June 2005 |
£2000 |
PharmaVitae 2005: Roche Global and US Analysis
|
June 2005 |
£3000 |
PharmaVitae 2005: Akzo Nobel Global & US Analysis
|
June 2005 |
£3000 |
PharmaVitae 2005: Lundbeck Global Analysis
|
June 2005 |
£2000 |
PharmaVitae 2005: Lundbeck Global & US Analysis
|
June 2005 |
£2000 |
Astellas Pharma Inc Deals Briefing
Partneringdesk
|
June 2005 |
£215 |
PharmaVitae 2005: Schering AG Global and US Analysis
|
May 2005 |
£3000 |
PharmaVitae 2005: Schering AG Global Analysis
|
May 2005 |
£2000 |
PharmaVitae 2005: Genentech Global and US Analysis
|
May 2005 |
£2000 |
PharmaVitae 2005: Genentech Global Analysis
|
May 2005 |
£2000 |
Sanofi-Aventis
OTC Company Profile
|
May 2005 |
£195 |
Pfizer Inc
|
May 2005 |
£195 |
Merck KGaA
|
May 2005 |
£195 |
Schering-Plough Corp
|
May 2005 |
£195 |
Merck Druggernaut; The
The Inside Story of a Pharmaceutical Giant
|
March 2005 |
£11.99 |
Market Leaders in Oncology 2004
Roche and Genentech Continue to Blaze a Trail
|
January 2005 |
£2000 |
Antithrombotics
Sanofi-Aventis the Dominant Player
|
December 2004 |
£8000 |
Roche Holding AG
OTC Healthcare Company Profile
|
September 2004 |
£195 |
OTC Healthcare Company Profile - Merck KGaA
|
